One thing the US Senate can agree on: It’s time to fix 340B

In a show of rare bipartisan agreement in the US Congress, lawmakers raised concerns over how the 340B program is driving up costs for patients, taxpayers and employers, and stressed the need for reforming the program, commented trade group Pharmaceuticals Research Manufacturers of America (PhRMA).

During a Senate Health, Education, Labor and Pensions (HELP) Committee hearing on October 23, lawmakers expressed concern about unchecked growth and lack of oversight, and questioned whether patients benefit.

The program lacks oversight